High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types

•TMB-H failed to predict improved or clinically relevant response to ICB in all cancer types.•Cancer types where TMB-H does not predict response generally show no relationship between tumor neoantigen load and CD8 T-cell infiltration.•Further studies should be carried out before application of TMB-H as a biomarker for ICB in all cancer types. BackgroundHigh tumor mutation burden (TMB-H) has been proposed as a predictive biomarker for response to...